Every material Form 8-K AETHLON MEDICAL INC has filed with the SEC since September 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At its virtual annual meeting on October 1, 2026, Aethlon Medical's stockholders elected five directors, approved an increase of 100,000 shares to the 2020 Equity Incentive Plan, and approved a series of other proposals. The filing also shows stockholders approved raising authorized common stock from 20,000,000 to 200,000,000 shares, which could allow future share issuance and dilution for holders of the current 711,136 outstanding shares.
Five directors elected, including Chetan S. Shah, MD and Nicolas Gikakis, each for terms ending at the next annual meeting
Stockholders approved a 100,000-share increase to the 2020 Equity Incentive Plan, effective October 1, 2026
Proposal to increase authorized common shares from 20,000,000 to 200,000,000 passed with 370,879 votes for and 27,208 against
Approximately 56.21% of the 711,136 eligible shares were represented, establishing a quorum
Aethlon Medical and private biotech North Immunology signed a merger agreement in which North Immunology becomes a wholly owned subsidiary of Aethlon and the combined company is renamed North Immunology, Inc. Pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company, while Aethlon stockholders also receive contingent value rights tied to proceeds, if any, from a sale or other monetization of its legacy Hemopurifier business.
Pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company; North Immunology holders, including Private Placement investors, about 95.25%
Concurrent private placement expected to provide about $180 million, including about $34 million from converted notes; closing requires at least $175 million in proceeds
Expected to close in the first quarter of 2027; either party may terminate if not closed by June 17, 2027; termination fees are $300,000 (Aethlon) and $2,000,000 (North Immunology) in specified cases
Combined company expected to trade on Nasdaq Capital Market under ticker NRTX and be led by North Immunology's CEO
Aethlon Medical amended the employment agreements of CEO and CFO James B. Frakes and Chief Medical Officer Steven P. LaRosa, M.D., on September 11, 2026. Under the amendments, if a change in control is completed and the executive is terminated in a way that triggers severance, installment severance and COBRA health care payments would be paid as a single lump sum. The filing states the amendments do not change the amount of severance or the circumstances that trigger it.
Amendments dated September 11, 2026, covering James B. Frakes (CEO and CFO) and Steven P. LaRosa, M.D. (Chief Medical Officer)
Severance installments become a single lump sum payable on the first regular payroll date after the release effective date, if a change in control and qualifying termination occur together
Health care continuation payments become a fixed lump sum equal to the COBRA period amount and are not reduced if the executive obtains other group coverage
The filing states the severance amounts and eligibility terms are unchanged
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AETHLON MEDICAL INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →